Stock Analiz

Hyperfine, Inc. HYPR

Biotechnology: Electromedical & Electrotherapeutic Apparatus · IPO 2021 · data as of November 13, 2026

$0.63Market cap $67M
Open the interactive analysis →

Hyperfine, Inc. (HYPR) is a healthcare company listed in the US with a market value of about $67M. In the twelve months to September 30, 2026 it had revenue of $19M and net income of -$30M, a net margin of -156.4%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 115% a year, a 5-year average ROIC of -66%.

About Hyperfine

Hyperfine is listed in the US and classified in biotechnology: electromedical & electrotherapeutic apparatus, IPO year 2021. Revenue went from $294000 in 2020 to $14M in 2025, growth of about 115.2% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 16% over three years (dilution for shareholders). It spends 129% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S3.5
P/B2.1
EV/EBITDA—
PEG—
Dividend yield—
FCF yield-41.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)5.2%
Revenue growth (5 yrs, per year)115.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1192.7%
ROIC (5-yr avg.)-65.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$19M$14M$13M$11M$7M$1M$294000
Net income-$30M-$36M-$41M-$44M-$44M-$65M-$23M
Free cash flow-$28M-$29M-$39M-$43M-$73M-$50M-$23M
EPS (diluted)$-0.29$-0.43$-0.56$-0.62$-1.04$-17.57$-15.38
Net margin-156.4%-262.3%-315.9%-401.0%-649.2%-4335.0%-7968.4%
ROIC—-89.8%-87.5%-56.8%-59.7%-34.8%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Hyperfine pay a dividend?

Not currently.

Is Hyperfine a good stock to buy?

We do not give buy or sell advice. Hyperfine scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.